We are live on ! Find out more
ABG

Ally Bridge Group Portfolio holdings

AUM $124M
1-Year Est. Return 249.88%
This Fund
S&P 500
This Quarter Est. Return
+7.88%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$76.3M
AUM Growth
-$26.5M
Cap. Flow
-$21M
Cap. Flow %
-27.59%
Top 10 Hldgs %
86.7%
Holding
43
New
13
Increased
–
Reduced
2
Closed
25

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$10.5M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$9.86M
3
CYTK icon
Cytokinetics
CYTK
+$9.11M
4
BLU
BELLUS Health Inc.
BLU
+$8.78M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$8.07M

Top Sells

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$8.58M
2
WHWK
Whitehawk Therapeutics
WHWK
+$8.12M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$7.56M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$6.22M
5
ALLK
Allakos
ALLK
+$5.24M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNLI icon
26
Denali Therapeutics
DNLI
$3.67B
– –
-4,479
Closed -$125K
LKFT
27
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-140,054
Closed -$6.22M
IRWD icon
28
Ironwood Pharmaceuticals
IRWD
$611M
– –
-326,428
Closed -$4.04M
KPTI icon
29
Karyopharm Therapeutics
KPTI
$168M
– –
-59,775
Closed -$3.05M
NAUT icon
30
Nautilus Biotechnolgy
NAUT
$215M
– –
-159,232
Closed -$287K
NKTR icon
31
Nektar Therapeutics
NKTR
$2.39B
– –
-88,977
Closed -$3.02M
PRAX icon
32
Praxis Precision Medicines
PRAX
$9.07B
– –
-42,039
Closed -$1.5M
RARE icon
33
Ultragenyx Pharmaceutical
RARE
$2.65B
– –
-185,261
Closed -$8.58M
RCKT icon
34
Rocket Pharmaceuticals
RCKT
$348M
– –
-125,176
Closed -$2.45M
RGEN icon
35
Repligen
RGEN
$7.44B
– –
-12,180
Closed -$2.06M
RNAC icon
36
Cartesian Therapeutics
RNAC
$232M
– –
-85,282
Closed -$2.89M
SAGE
37
DELISTED
Sage Therapeutics
SAGE
– –
-119,008
Closed -$4.54M
SANA icon
38
Sana Biotechnology
SANA
$885M
– –
-1,015,273
Closed -$4.01M
WHWK
39
Whitehawk Therapeutics
WHWK
$183M
– –
-632,997
Closed -$8.12M
MOR
40
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-405,602
Closed -$1.45M
SNCE
41
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
– –
-19,220
Closed -$160K
MRTX
42
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-47,520
Closed -$2.15M
SGEN
43
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-37,639
Closed -$4.84M
1
2

Similar funds

MP
Marcho Partners London, United Kingdom $124M AUM 15.03% 1-Year Est. Return
EWP
E-Wealth Partners Minnetonka, Minnesota $124M AUM
WFA
WJ Financial Advisors Killingworth, Connecticut $124M AUM
VWM
Vigil Wealth Management Ponte Vedra Beach, Florida $124M AUM
EI
EDMP Inc Lutz, Florida $124M AUM 19.53% 1-Year Est. Return
TC
Town Capital Bel Air, Maryland $124M AUM
IFO
Intrepid Family Office Sarasota, Florida $124M AUM 37.91% 1-Year Est. Return
CRW
Clarity Retirement & Wealth New Bedford, Massachusetts $124M AUM

Ally Bridge Group's Q1 2023 Portfolio in Review

As of Q1 2023, Ally Bridge Group held 43 positions worth $76.3M, down 26% from $103M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Ally Bridge Group withdrew a net $21M in Q1 2023, closing 25 positions and reducing 2 holdings. Its most notable exit was Ultragenyx Pharmaceutical, an estimated $8.58M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Ally Bridge Group opened a new position in Verona Pharma worth $9.79M.

  • Ally Bridge Group's largest Q1 2023 buy was Verona Pharma: 487,631 shares worth $9.79M.
  • Ally Bridge Group's biggest Q1 2023 reduction was Syros Pharmaceuticals, Inc. Common Stock, cutting an estimated $2.4M.
  • Ally Bridge Group fully exited Ultragenyx Pharmaceutical in Q1 2023, selling an estimated $8.58M.
  • Ally Bridge Group's ten largest holdings make up 87% of its $76.3M portfolio in Q1 2023.
  • Ally Bridge Group opened 13 new positions and closed 25 in Q1 2023.
  • Ally Bridge Group's portfolio value fell 26% quarter-over-quarter to $76.3M.

Based on Ally Bridge Group's 13F filing for Q1 2023, filed 15 May 2023.